{"id":"https://openalex.org/W2406890959","doi":"https://doi.org/10.1080/13696998.2016.1194278","title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","display_name":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","publication_year":2016,"publication_date":"2016-05-25","ids":{"openalex":"https://openalex.org/W2406890959","doi":"https://doi.org/10.1080/13696998.2016.1194278","mag":"2406890959","pmid":"https://pubmed.ncbi.nlm.nih.gov/27224006"},"language":"en","primary_location":{"id":"doi:10.1080/13696998.2016.1194278","doi":"https://doi.org/10.1080/13696998.2016.1194278","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2016.1194278","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1194278?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1194278?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057911528","display_name":"Andrzej J. Jakubowiak","orcid":"https://orcid.org/0000-0002-2597-6822","observed_orcids":["https://orcid.org/0000-0002-2597-6822"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrzej J. Jakubowiak","raw_affiliation_strings":["Myeloma Program, University of Chicago, Chicago, IL, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Program, University of Chicago, Chicago, IL, USA;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108673058","display_name":"Marco Campioni","orcid":"https://orcid.org/0000-0002-4373-1669","observed_orcids":["https://orcid.org/0000-0002-4373-1669"]},"institutions":[{"id":"https://openalex.org/I4210139000","display_name":"Amgen (Switzerland)","ror":"https://ror.org/045wjte67","country_code":"CH","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210139000"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Marco Campioni","raw_affiliation_strings":["Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland;","institution_ids":["https://openalex.org/I4210139000"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000218289","display_name":"\u00c1gnes Benedict","orcid":"https://orcid.org/0000-0002-4747-4575","observed_orcids":["https://orcid.org/0000-0002-4747-4575"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"\u00c1gnes Benedict","raw_affiliation_strings":["Modeling and Simulation, Evidera, Budapest, Hungary;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Modeling and Simulation, Evidera, Budapest, Hungary;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055349619","display_name":"Ivan Houisse","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivan Houisse","raw_affiliation_strings":["Modeling and Simulation, Evidera, Budapest, Hungary;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Modeling and Simulation, Evidera, Budapest, Hungary;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089860997","display_name":"Eszter Tichy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eszter Tichy","raw_affiliation_strings":["Modeling and Simulation, Evidera, Budapest, Hungary;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Modeling and Simulation, Evidera, Budapest, Hungary;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003244323","display_name":"Andromachi Giannopoulou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139000","display_name":"Amgen (Switzerland)","ror":"https://ror.org/045wjte67","country_code":"CH","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210139000"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Andromachi Giannopoulou","raw_affiliation_strings":["Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland;","institution_ids":["https://openalex.org/I4210139000"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112233910","display_name":"Sanjay Kumar Aggarwal","orcid":"https://orcid.org/0009-0009-9156-7910","observed_orcids":["https://orcid.org/0009-0009-9156-7910"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay K. Aggarwal","raw_affiliation_strings":["Global Development, Amgen Inc., Thousand Oaks, CA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Development, Amgen Inc., Thousand Oaks, CA, USA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108620199","display_name":"Beth Barber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beth L. Barber","raw_affiliation_strings":["Global Development, Amgen Inc., Thousand Oaks, CA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Development, Amgen Inc., Thousand Oaks, CA, USA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087574931","display_name":"Sumeet S. Panjabi","orcid":"https://orcid.org/0000-0002-5093-8510","observed_orcids":["https://orcid.org/0000-0002-5093-8510"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumeet Panjabi","raw_affiliation_strings":["Global Health Economics, Amgen Inc. San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics, Amgen Inc. San Francisco, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5057911528"],"corresponding_institution_ids":["https://openalex.org/I40347166"],"apc_list":null,"apc_paid":null,"fwci":13.7465,"has_fulltext":true,"cited_by_count":52,"citation_normalized_percentile":{"value":0.98568083,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":99},"biblio":{"volume":"19","issue":"11","first_page":"1061","last_page":"1074"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.6342999935150146,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.6342999935150146,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.357699990272522,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":0.9829999804496765},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9470000267028809},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":1.0},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9300000071525574},{"id":"https://openalex.org/keywords/aspire-trial","display_name":"ASPIRE trial","score":0.8740000128746033},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8289999961853027},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.9279999732971191},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7279999852180481},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9470000267028809},{"id":"https://openalex.org/keywords/health-utility","display_name":"health utility","score":0.5329999923706055},{"id":"https://openalex.org/keywords/drug-reimbursement","display_name":"drug reimbursement","score":0.4580000042915344},{"id":"https://openalex.org/keywords/united-states","display_name":"United States","score":0.49399998784065247}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.8774670362472534},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8211549520492554},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8035265207290649},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5688806176185608},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.49072587490081787},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.4814528822898865},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.47957247495651245},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4308536946773529},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.42349761724472046},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3807355761528015},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018803","descriptor_name":"Models, Economic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/13696998.2016.1194278","doi":"https://doi.org/10.1080/13696998.2016.1194278","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2016.1194278","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1194278?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:27224006","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27224006","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/13696998.2016.1194278","doi":"https://doi.org/10.1080/13696998.2016.1194278","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2016.1194278","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1194278?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2406890959.pdf","grobid_xml":"https://content.openalex.org/works/W2406890959.grobid-xml"},"referenced_works_count":37,"referenced_works":["https://openalex.org/W173435793","https://openalex.org/W1535093614","https://openalex.org/W1835672070","https://openalex.org/W1840834976","https://openalex.org/W1970681172","https://openalex.org/W1978393082","https://openalex.org/W1985864219","https://openalex.org/W1992538067","https://openalex.org/W2021954218","https://openalex.org/W2044415411","https://openalex.org/W2058056848","https://openalex.org/W2095745169","https://openalex.org/W2106545856","https://openalex.org/W2110046944","https://openalex.org/W2126499930","https://openalex.org/W2133268402","https://openalex.org/W2134047636","https://openalex.org/W2139672960","https://openalex.org/W2141165931","https://openalex.org/W2145102719","https://openalex.org/W2148199952","https://openalex.org/W2150878522","https://openalex.org/W2168432303","https://openalex.org/W2189701884","https://openalex.org/W2193716145","https://openalex.org/W2201190784","https://openalex.org/W2247202309","https://openalex.org/W2332257146","https://openalex.org/W2343386476","https://openalex.org/W2397184192","https://openalex.org/W2521654387","https://openalex.org/W2549580878","https://openalex.org/W2598354676","https://openalex.org/W3123205228","https://openalex.org/W3195431600","https://openalex.org/W4252175385","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2892083382","https://openalex.org/W2982423776","https://openalex.org/W2761712406","https://openalex.org/W2995144404","https://openalex.org/W6977562038","https://openalex.org/W2947966808","https://openalex.org/W7065512716","https://openalex.org/W2020368872","https://openalex.org/W2322208802","https://openalex.org/W1989778394"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"assess":[2],"the":[3,12,27,47,81,89,137,153,190,215,219,259,287],"economic":[4],"value":[5,237],"of":[6,29,67,83,158,228,251,261,272,275,286],"carfilzomib":[7],"(Kyprolis),":[8],"this":[9],"study":[10],"developed":[11],"Kyprolis":[13],"Global":[14],"Economic":[15],"Model":[16],"(K-GEM),":[17],"which":[18],"examined":[19],"from":[20,46,225],"a":[21,116,226,269],"United":[22],"States":[23],"(US)":[24],"payer":[25],"perspective":[26],"cost-effectiveness":[28,203],"carfilzomib-lenalidomide-dexamethasone":[30],"(KRd)":[31],"versus":[32],"lenalidomide-dexamethasone":[33],"(Rd)":[34],"in":[35,88,197,218],"relapsed":[36],"multiple":[37],"myeloma":[38],"(RMM;":[39],"1-3":[40],"prior":[41,266],"therapies)":[42,267],"based":[43],"on":[44],"results":[45],"phase":[48],"III":[49],"ASPIRE":[50,79,131],"trial":[51,90],"that":[52,62],"directly":[53],"compared":[54,175],"these":[55],"regimens.":[56],"METHODS:":[57],"A":[58],"partitioned":[59],"survival":[60,95,98,140,212],"model":[61],"included":[63],"three":[64],"health":[65,148,239],"states":[66],"progression-free":[68,94],"(on":[69],"or":[70],"off":[71],"treatment),":[72],"post-progression,":[73],"and":[74,96,113,122,165,182,230],"death":[75],"was":[76,91,141,169,206],"developed.":[77],"Using":[78],"data,":[80],"effect":[82],"treatment":[84,260],"regimens":[85],"as":[86],"administered":[87],"assessed":[92],"for":[93,109,145,160,258,277],"overall":[97],"(OS).":[99],"Treatment":[100],"effects":[101],"were":[102,128,223],"estimated":[103,170],"with":[104,163,248,263,279],"parametric":[105],"regression":[106],"models":[107],"adjusting":[108],"baseline":[110],"patient":[111],"characteristics":[112],"applied":[114],"over":[115,189],"lifetime":[117],"horizon.":[118,192],"US":[119,235],"Surveillance,":[120],"Epidemiology":[121],"End":[123],"Results":[124],"(1984-2014)":[125],"registry":[126],"data":[127],"matched":[129],"to":[130,133,143,171,176,232],"patients":[132,161,194,236,262,278],"extrapolate":[134],"OS":[135],"beyond":[136],"trial.":[138],"Estimated":[139],"adjusted":[142],"account":[144],"utilities":[146],"across":[147],"states.":[149],"The":[150,201,242],"K-GEM":[151,243],"considered":[152],"total":[154,198],"direct":[155],"costs":[156],"(pharmacy/medical)":[157],"care":[159],"treated":[162],"KRd":[164,168,245,276],"Rd.":[166],"RESULTS:":[167],"be":[172],"more":[173],"effective":[174],"Rd,":[177],"providing":[178],"1.99":[179],"life":[180,185],"year":[181,186],"1.67":[183],"quality-adjusted":[184],"(QALY)":[187],"gains":[188],"modeled":[191,220],"KRd-treated":[193],"incurred":[195],"$179,393":[196],"additional":[199],"costs.":[200],"incremental":[202],"ratio":[204],"(ICER)":[205],"$107,520":[207,252],"per":[208,253],"QALY.":[209],"LIMITATIONS:":[210],"Extrapolated":[211],"functions":[213],"present":[214],"greatest":[216],"uncertainty":[217],"results.":[221],"Utilities":[222],"derived":[224],"combination":[227],"sources":[229],"assumed":[231],"reflect":[233],"how":[234],"their":[238],"state.":[240],"CONCLUSIONS:":[241],"showed":[244],"is":[246],"cost-effective,":[247],"an":[249,283],"ICER":[250],"QALY":[254],"gained":[255],"against":[256],"Rd":[257],"RMM":[264,280],"(1-3":[265],"at":[268],"willingness-to-pay":[270],"threshold":[271],"$150,000.":[273],"Reimbursement":[274],"may":[281],"represent":[282],"efficient":[284],"allocation":[285],"healthcare":[288],"budget.":[289]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}